Neuro Drug Focus (NDF) is a new business news service that will keep you fully updated with the latest developments in neurodegenerative product registration, agreements and clinical trials. In addition, NDF summarises key research presented at international conferences and in journals, and features special articles focusing on companies or topics that are influencing this sector.
Aged populations are expected to grow to unprecedented levels in the next 20 years, having a major impact on the incidence of neurodegenerative diseases. For example, according to the WHO, by 2025 there will be 34 million people with Alzheimers disease. Consequently, industry attention is focusing as never before on the need to provide effective treatments.
Regular sections in NDF include:
- Alzheimers Disease
- Multiple Sclerosis
- Parkinsons Disease
- Rarer Disorders (ALS, Huntingtons disease, Spinocerebellar ataxia, spinal muscular atrophy, palsy, CJD/TSE, mild cognitive impairment)
Neuro Drug Focus (NDF) published by Espicom Business Intelligence. This newsletter price starts from US $ 1025.